Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02263885 · ClinicalTrials.gov registry record · NA
ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02263885: Completed NA study, sponsored by InSightec.
NCT02263885 is a NA study that has completed, run by InSightec. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02263885, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 30 years of age and considered medication-refractory with advanced idiopathic Parkinson's disease (PD).
Primary Outcome
The primary outcome of this feasibility trial was safety. Adverse Events were categorized by physicians as mild, moderate, or severe. Events resulting in impairment, requiring intervention to preclude impairment, or that were life threatening, and deaths were reported by physicians as Serious Adverse Events. Outcomes are entered in the adverse events module.
Interventions
- DEVICE ExAblate Transcranial System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-07-26 |
| Phase | NA |
What the finished NCT02263885 record still lists
NCT02263885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which ExAblate Transcranial System is the first listed.
NCT02263885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02263885 about?
NCT02263885 is a clinical study titled "ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease". The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 30 years of age and considered medication-refractory with advanced idiopathic Parkinson's...
What is the current status of trial NCT02263885?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-04. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT02263885?
The interventions under investigation include: ExAblate Transcranial System (DEVICE).
Who is sponsoring clinical trial NCT02263885?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02263885's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia